<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biorestorative Therapies Inc — News on 6ix</title>
<link>https://6ix.com/company/biorestorative-therapies-inc</link>
<description>Latest news and press releases for Biorestorative Therapies Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biorestorative-therapies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354fb078dffbe2df0e6e31.webp</url>
<title>Biorestorative Therapies Inc</title>
<link>https://6ix.com/company/biorestorative-therapies-inc</link>
</image>
<item>
<title>BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-announces-strategic-partnership-with-global-dermatology-leader-dr-david-j-goldberg-to-lead-clinical-evaluation-and-seek-multi-channel-adoption-of-its-regenerative-biocosmeceutical-platform</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-announces-strategic-partnership-with-global-dermatology-leader-dr-david-j-goldberg-to-lead-clinical-evaluation-and-seek-multi-channel-adoption-of-its-regenerative-biocosmeceutical-platform</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for</description>
</item>
<item>
<title>BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-build-and-commercialize-biocosmeceutical-platform</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-build-and-commercialize-biocosmeceutical-platform</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging biotechnology and premium</description>
</item>
<item>
<title>BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-reports-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-reports-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities</description>
</item>
<item>
<title>BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured</description>
</item>
<item>
<title>BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-inc-to-participate-in-the-bewell-beauty-and-wellness-show-in-new-york-city-march-8-10-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-inc-to-participate-in-the-bewell-beauty-and-wellness-show-in-new-york-city-march-8-10-2026-4</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026</description>
</item>
<item>
<title>BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-inc-issues-letter-to-shareholders-highlighting-major-milestones-regulatory-alignment-clinical-execution-and-capital-strategy-11</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-inc-issues-letter-to-shareholders-highlighting-major-milestones-regulatory-alignment-clinical-execution-and-capital-strategy-11</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million</description>
</item>
<item>
<title>BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-expands-global-protection-for-thermostemr-a-potentially-longer-lasting-and-safer-cell-based-alternative-to-glp-1-drugs</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-expands-global-protection-for-thermostemr-a-potentially-longer-lasting-and-safer-cell-based-alternative-to-glp-1-drugs</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innova</description>
</item>
<item>
<title>BioRestorative Announces Closing of $5.0 Million Public Offering</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-announces-closing-5-0-013000159</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-announces-closing-5-0-013000159</guid>
<pubDate>Sat, 14 Feb 2026 01:30:00 GMT</pubDate>
<description>MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of</description>
</item>
<item>
<title>BioRestorative Announces Pricing of $5.0 Million Public Offering</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-announces-pricing-5-0-033000521</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-announces-pricing-5-0-033000521</guid>
<pubDate>Thu, 12 Feb 2026 03:30:00 GMT</pubDate>
<description>MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the pricing of a public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre</description>
</item>
<item>
<title>BioRestorative Announces Positive Outcome from Type B Meeting with FDA</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-announces-positive-outcome-type-123000247</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-announces-positive-outcome-type-123000247</guid>
<pubDate>Wed, 11 Feb 2026 12:30:00 GMT</pubDate>
<description>BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of chronic lumbar disc disease (“cLDD”)Consistent positive clinical safety endpoints from BioRestorative’s ongoing 99 patient Phase 2 clinical trial of BRTX-100 in cLDD were discussed in the meeting and the FDA did not raise any clinical safety concerns</description>
</item>
<item>
<title>BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-completes-patient-enrollment-landmark-130000730</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-completes-patient-enrollment-landmark-130000730</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placeboProspective, randomized, double-blind, sham-controlled single-disc study — gold-standard clinical designEnrollment completion strengthens regulatory pathway toward Phase 3 and potential BLA filing MELVILLE, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative</description>
</item>
<item>
<title>BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-granted-type-b-meeting-120000465</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-granted-type-b-meeting-120000465</guid>
<pubDate>Mon, 17 Nov 2025 12:00:00 GMT</pubDate>
<description>MELVILLE, N.Y., Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has been granted a Type B meeting with the U.S. Food and Drug Administration (“FDA”) to discuss a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of chronic</description>
</item>
<item>
<title>BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-reports-third-quarter-210500428</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-reports-third-quarter-210500428</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>MELVILLE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the third quarter ended September 30, 2025 and provided an update on its business. “As energized as we are by the strong clinical development advancement and positive business momentum that has characterized 2025 so far, in many ways, we</description>
</item>
<item>
<title>BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-report-third-quarter-213000425</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-report-third-quarter-213000425</guid>
<pubDate>Wed, 05 Nov 2025 21:30:00 GMT</pubDate>
<description>MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.</description>
</item>
<item>
<title>BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-awarded-notice-allowance-japanese-113000730</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-awarded-notice-allowance-japanese-113000730</guid>
<pubDate>Mon, 27 Oct 2025 11:30:00 GMT</pubDate>
<description>MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced a major intellectual property milestone: the Japanese Patent Office has issued a Notice of Allowance for the Company’s ThermoStem® platform. The newly allowed patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown adipose-derive</description>
</item>
<item>
<title>BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-strengthens-commercial-leadership-appointment-133500172</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-strengthens-commercial-leadership-appointment-133500172</guid>
<pubDate>Wed, 22 Oct 2025 13:35:00 GMT</pubDate>
<description>MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative’s global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthet</description>
</item>
<item>
<title>BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-participate-2025-maxim-133500504</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-participate-2025-maxim-133500504</guid>
<pubDate>Wed, 15 Oct 2025 13:35:00 GMT</pubDate>
<description>MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. Lance Alstodt, BioRestorative’s CEO, and Francisco Silva, the Company’s Vice President of Research and Development, will be p</description>
</item>
<item>
<title>BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-ceo-lance-alstodt-interviewed-132500491</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-ceo-lance-alstodt-interviewed-132500491</guid>
<pubDate>Tue, 07 Oct 2025 13:25:00 GMT</pubDate>
<description>MELVILLE, N.Y., Oct. 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today is pleased to announce that its CEO, Lance Alstodt, participated in an interview with “The Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio show. During the interview, Mr. Alstodt discussed BioRestorative’s recent achievements of key clinical and</description>
</item>
<item>
<title>BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-announces-1-085-182800767</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-announces-1-085-182800767</guid>
<pubDate>Mon, 06 Oct 2025 18:28:00 GMT</pubDate>
<description>MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into definitive agreements with several accredited and/or institutional investors for the sale of 678,125 shares of the Company’s common stock at an offering price of $1.60 per share in a registered direct offering. The Company’s stock closed at $1.50 per share on</description>
</item>
<item>
<title>BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-reports-second-quarter-200500129</link>
<guid isPermaLink="true">https://6ix.com/company/biorestorative-therapies-inc/news/biorestorative-therapies-reports-second-quarter-200500129</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its business. “We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025,” said Lance Alst</description>
</item>
</channel>
</rss>